APPLICANT NAME					
ORGANISATION					
PROPOSAL TITLE					
Category:	Description of relevant attributes:	Value descriptor:	Mark Selection with X	Available Score (0 - 3)	Awarded Score
I. Strategic Fit/Innovation value				. , ,	
Describe how the innovation aligns with CL	JHP's strategy of supporting and accelerating the development of	of			
innovative medical technologies to improve patient safety		Does not align with current strategy		0	
		Modest fit; links to some low priority elements of strategy		1	
		Good fit; links to some key elements of strategy		2	
		Perfect alignment; positive associative benefits to CUHP		3	
Project enables creation of unique patient advantages	Describe the advantage to patients	No unique benefits to patient Minor benefits to patient, compared to current technique/device Some measurable benefit to patient Clear evidence of providing important benefit to patient		0 1 2 3	
Project enables creation of healthcare	Describe the advantages to healthcare provider	T			
provider benefits		No unique benefits to healthcare provider		0	
		Minor benefits to healthcare provider, compared to current technique/device		1	
		Some measurable benefit to healthcare provider		2	
		Clear evidence of providing important benefit to healthcare provider		3	
II. Development Risk		Total Development Risk	7		
Current status	Describe the status of the innovation	Idea creation		0	
Can come status		The idea is developed (eg a needs statement has been developed)		1	
		A prototype is available		2	
		A prototype has been tested with positive results		3	
Funding	Describe how the development is currently funded	Funding has not been identified		0	
	pesende non the development is currently funded	Public funding source has been identified and innovation meets grant criteria		1	
		Grant applied for/private funding is in progress		2	
		Grant/private funding awarded		3	1
Regulatory clearance	Describe how the innovation will likely be classified by the				
negulatory clearance	regulatory bodies	Unknown		0	
		Class III (FDA);		1	
		Class II (FDA)		2	1
		Class I/Exempt (FDA)		3	

APPLICANT NAME					
ORGANISATION					
PROPOSAL TITLE					
Category:	Description of relevant attributes:	Value descriptor:	Mark Selection with X	Available Score (0 - 3)	Awarded Score
Ethics Approval	Describe the potential challenges in achieving ethics approval		1		
	for trials	Unknown		0	
	-	Anticipate high patient risk in trial participation		1	
		Anticipate moderate patient risk in trial participation		2	
		Anticipate low patient risk in trial participation		3	
IP .	Describe the idea's patentability and status	Unknown	T	0	
	, , , , , , , , , , , , , , , , , , , ,	Complex IP Landscape, potential freedom to operate issues		1	
		Likely patentable but freedom to operate status unknown		2	
		Likely patentable and field is clear of blocking IP		3	
III. Market & Financial Considerations			1		
Commercial Landscape	Describe the dynamics in the intended market	Market undeveloped		0	
	-	Market dominated by 1-2 major companies		1	
		Competitive market with several suppliers		2	
		Highly fragmented market		3	
Market acceptance of innovation					
	Describe how innovation has been adopted in intended market	Negligible adoption of innovative procedures/devices in past 5 years		0	
		Low adoption rate for devices/procedures introduced in past 5 years		1	
		Moderate adoption rate for devices/procedures introduced in past 5 years		2	
		Rapid adoption rate for devices/procedures introduced in past 5 years		3	
Current market size* £	Estimate the market size	Low <£50m		0	
	0	Moderate £50m - £200m		1	
		Good £200m - £1bn		2	
		Excellent £1bn +		3	
Estimated cost of development	Provide background to estimate of cost	High >£50m		0	
	-	Moderate £15m-£50m		1	
		Modest £5m-£15m		2	
		Low <£5m		3	
Time to commercialisation	Provide background to estimate of time	>5 years	T	0	
		3-5 years		1	
		1-2 years		2	
		<1 year		3	
IV. Overall Risk vs. Benefit Assessment			7		
		Can not be estimated		0	
		Low benefit/high risk		1	
		Medium benefit/medium risk		2	
		High benefit/low risk		3	
			То	tal Score	
EXPERT PANEL MEMBER	NAME:	SIGNATURE	DATE:		
LACINI PANCI IVICIVIDER	I I WALLY I	1.305 (1994 1.105)	HIJALIE		

Page 2 of 2